Table 4 Univariate and multivariate analysis according to stage

AJCC stage I

Serum AFP (≥ 400 ng/mL)

1.523 (0.412-5.629)

0.528

1.490 (0.394-5.649)

Serum PIVKA-II (≥ 300 mAU/mL)

9.317 (2.736-30.453)

< 0.001

8.771 (2.538-30.303)

PT (≤ 80%)

1.862 (0.503-6.896)

0.352

0.746 (0.164-3.397)

Platelet count (≤ 130 × 10³/μL)

4.608 (1.250-16.949)

0.022

4.948 (1.097-22.322)

AJCC stage II

Serum AFP (≥ 400 ng/mL)

3.484 (1.233-9.803)

0.018

2.832 (0.983-8.196)

Serum PIVKA-II (≥ 300 mAU/mL)

3.984 (1.466-10.989)

0.008

3.355 (1.179-9.523)

PT (≤ 80%)

1.198 (0.434-3.305)

0.728

1.167 (0.382-3.564)

Platelet count (≤ 130 × 10³/μL)

1.164 (1.413-3.267)

0.773

0.820 (0.265-2.542)

AJCC stage III

Serum AFP (≥ 400 ng/mL)

1.037 (0.586-1.834)

0.899

1, 164 (0.652-2.078)

Serum PIVKA-II (≥ 300 mAU/mL)

2.252 (1.116-4.545)

0.023

2.212 (1.086-4.504)

PT (≤ 80%)

1.192 (0.659-2, 158)

0.561

1.254 (0.685-2.296)

Platelet count (≤ 130 × 10³/μL)

1.934 (1.062-3.522)

0.031

1.868 (1.017-3.428)

BCLC stage A

Serum AFP (≥ 400 ng/mL)

1.934 (1.094-3.424)

0.023

2.544 (1.003-6.451)

Serum PIVKA-II (≥ 300 mAU/mL)

9.319 (3.856-22.525)

< 0.001

8.403 (3.424-20.408)

PT (≤ 80%)

1.845 (0.714-4.761)

0.206

1.098 (0.404-2.9984)

Platelet count (≤ 130 × 10³/μL)

2.127 (0.896-5.050)

0.087

2.055 (0.820-5.153)

BCLC stage B

Serum AFP (≥ 400 ng/mL)

1.183 (0.502-2.791)

0.701

1.163 (0.482-2.807)

Serum PIVKA-II (≥ 300 mAU/mL)

1.740 (0.715-4.232)

0.222

1.743 (0.711-4.271)

PT (≤ 80%)

1.054 (0.443-2.508)

0.905

1.142 (0.448-2.911)

Platelet count (≤ 130 × 10³/μL)

1.243 (0.461-2.710)

0.804

1.072 (0.424-2.712)

BCLC stage C

Serum AFP (≥ 400 ng/mL)

1.382 (0.656-2.910)

0.394

1.377 (0.610-3.105)

Serum PIVKA-II (≥ 300 AU/mL)

2.909 (1.015-8.333)

0.047

3.174 (1.098-9.174)

PT (≤ 80%)

0.800 (0385-1.659)

0.548

0.588 (0.258-1.338)

Platelet count (≤ 130 × 10³/μL)

1.642 (0.790-3.412)

0.184

1.917 (0.893-4.114)